View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Stijn Demeester
  • Stijn Demeester

AMG/Another beat and raise driven by antimony/BUY

We update our model to reflect AMG's strong beat on its 1Q25 results and guidance upgrade. We maintain our target price at €25, offering c.24% further upside, and reiterate our BUY.

 PRESS RELEASE

Melexis Appoints Two New Directors to Its Board of Directors

Melexis Appoints Two New Directors to Its Board of Directors Tessenderlo-Ham, Belgium – May 15, 2025 Melexis NV (Euronext Brussels: MELE), a global supplier of micro-electronic semiconductor solutions, announces the appointment of two new members to the board of directors following the approval by the annual shareholders’ meeting held on May 13, 2025. The announcement of Ms. Ling Qi and Mr. Kazuhiro Takenaka underlines Melexis’ focused ambitions in the Asia-Pacific Region (APAC). Ms. Ling Qi has more than 20 years of international business management experience. Currently, she is CEO of...

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

MFN Drug Pricing - Impact and Implementation (Thematic, 5pgs)

Ahead of today’s signing of an Executive Order to introduce a Most Favoured Nation approach to drug pricing in the US, we show that net pricing in the EU is c.50% lower than in the US & which companies have most to lose from MFN. We also show that, in reality,

ABGSC Energy Research ... (+6)
  • ABGSC Energy Research
  • Daniel Vårdal Haugland
  • John Olaisen
  • Njål Kleiven
  • Oliver Dunvold
  • Stian Wibstad
 PRESS RELEASE

Melexis: update on the share buy-back program

Melexis: update on the share buy-back program Press release - Regulated Information Ieper, Belgium – 12 May 2025, 17.45 hrs CET Further to the initiation of the share buy-back program announced on 10 December 2024, Melexis reports the purchase of 47,500 Melexis shares on Euronext Brussels in the period from 2 to 9 May 2025. Trade dateTotal shares purchasedAverage price (€)Min price (€)Max price (€)Buyback amount (€)2/5/20258,50054.5253.2554.95463,4505/5/20259,00054.2954.0555.05488,5866/5/20258,00053.2452.7554.30425,8947/5/20258,00053.4952.9553.70427,9198/5/20257,00054.4853.8055.10381,34...

 PRESS RELEASE

Melexis: update over het aandeleninkoopprogramma

Melexis: update over het aandeleninkoopprogramma Persbericht - Gereglementeerde informatie Ieper, België – 12 mei 2025, 07.00 uur CET Naar aanleiding van het aandeleninkoopprogramma dat op 10 december 2024 werd aangekondigd, maakt Melexis bekend dat er 47.500 eigen aandelen ingekocht werden op Euronext Brussel tussen 2 en 9 mei 2025. InkoopdatumAantal verworven aandelenGemiddelde prijs (€)Laagste prijs (€)Hoogste prijs (€)Aankoop bedrag (€)2/5/20258.50054,5253,2554,95463.4505/5/20259.00054,2954,0555,05488.5866/5/20258.00053,2452,7554,30425.8947/5/20258.00053,4952,9553,70427.9198/5/20257...

Novo Nordisk AS: 1 director

A director at Novo Nordisk AS sold 40,000 shares at 450.528DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

ABGSC Energy Research ... (+6)
  • ABGSC Energy Research
  • Daniel Vårdal Haugland
  • John Olaisen
  • Njål Kleiven
  • Oliver Dunvold
  • Stian Wibstad
ABGSC Renewable Energy Research ... (+3)
  • ABGSC Renewable Energy Research
  • Åsne Holsen
  • Daniel Vårdal Haugland
Rune Majlund Dahl
  • Rune Majlund Dahl

Zealand Pharma (Buy, TP: DKK950.00) - Dapiglutide likely next catalyst

Q1 revenue missed expectations on lower reimbursement revenue, while operating profit was a beat, as opex was below our forecast and consensus. The 2025 guidance was maintained for opex of DKK2,000m–2,500m. We believe the next potential share-price catalyst is the top-line results from the phase Ib dapiglutide trial in Q2e. We reiterate our BUY, but have cut our target price to DKK950 (1,000).

 PRESS RELEASE

AMG Announces Results of its 2025 Annual General Meeting

AMG Announces Results of its 2025 Annual General Meeting Amsterdam, 8 May 2025 (Regulated Information) --- AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) is pleased to announce that during its Annual General Meeting held on May 8, 2025, shareholders approved all agenda items presented. During the meeting, Dr. Heinz Schimmelbusch was reappointed as Chief Executive Officer for an additional term of two years, beginning May 8, 2025. At this Annual General Meeting, the term of AMG’s Chief Operating Officer, Mr. Eric Jackson, has ended and he has indicated his plan to retire. Mr...

 PRESS RELEASE

AMG Announces Final 2024 Dividend 

AMG Announces Final 2024 Dividend  Amsterdam, 8 May 2025 (Regulated Information) --- AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) is pleased to announce that during the Annual General Meeting, held on May 8, 2025, AMG's shareholders approved the payment of a dividend of €0.40 per ordinary share over the financial year 2024. The interim dividend of €0.20, paid on August 14, 2024, was deducted from the amount distributed to shareholders. The final dividend per ordinary share therefore amounts to €0.20. Payment of the final dividend will be completed on or around May 15, 202...

Louis Boujard ... (+3)
  • Louis Boujard
  • CFA
  • Philippe Ourpatian
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch